Successful examples include targeting B cells with high affinity glycan ligands of CD22 (Siglec-2) which results in an effective depletion of B cell lymphoma in vitro and in vivo[11], [32] and targeting eosinophils using a multivalent glycan ligands of Siglec-8, which induces apoptosis of eosinophils and could be useful in controlling eosinophilic inflammatory responses [33]. Here, CD22 is linked to B-cell non-Hodgkin lymphoma.